Response to cabergoline treatment, gonadal axis recovery, and outcomes of drug withdrawal, in men with microprolactinoma: a retrospective cohort study
Ninety percent of men harboring microprolactinoma achieved normoprolactinemia and subsequent testosterone normalization with cabergoline treatment. Men that discontinued cabergoline after prolonged prolactin suppression (>5 years) achieved sustained remission. These findings assist informed decision-making, between medical and surgical treatment.
Authors
- Hadar Duskin‐Bitan (ORCID: https://orcid.org/0000-0002-1721-1360)
- Gloria Tsvetov (ORCID: https://orcid.org/0000-0002-2033-7300)
- Yaron Rudman (ORCID: https://orcid.org/0000-0003-3220-6321)
- Efrat Markus
- Genady Drozdinsky (ORCID: https://orcid.org/0000-0003-2166-3906)
- Nicolas Simon (ORCID: https://orcid.org/0000-0003-4393-2257)
- Amit Akirov (ORCID: https://orcid.org/0000-0002-9376-344X)
- Hiba Masri‐Iraqi (ORCID: https://orcid.org/0000-0002-0889-8025)
- Ilan Shimon (ORCID: https://orcid.org/0000-0002-9188-3894)
- Rona Shimon
Institutions
- Semmelweis University (HU)
- Tel Aviv University (IL)
- Rabin Medical Center (IL)
- Assaf Harofeh Medical Center (IL)
- Clalit Health Services (IL)
Publication Details
- Journal
- Endocrine
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1007/s12020-025-04215-w
- Citations
- 7
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 9.06
Funders
- Tel Aviv University